Short or long radiation course before surgery for rectal cancer
Part of Cancer, Digestive system clinical trials.
This trial compares a shorter course of radiation (given over 1 week) versus the usual longer course (over 5–6 weeks) before surgery for locally advanced rectal cancer. The goal is to see if the shorter course works just as well and is more convenient.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with adenocarcinoma (a common type) of the rectum.
- The cancer is locally advanced, meaning it has grown into or through the rectal wall or spread to nearby lymph nodes, but has not spread to distant organs.
- The tumor is within about 15 cm (6 inches) from the anal opening.
- You are in reasonably good health and able to care for yourself (ECOG 0-2).
- Your blood counts and liver/kidney function are within acceptable ranges.
- You have not had prior radiation to the pelvis or chemotherapy for rectal cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a short course of radiation with chemotherapy, targeted therapy, and immunotherapy before surgery for locally advanced rectal cancer. It aims to shrink the tumor and improve outcomes.
This trial tests a short course of radiation given before chemotherapy for people with locally advanced rectal cancer (cancer that has grown into nearby tissue and/or nearby lymph nodes but can still be removed). It may help shrink the tumor and make treatment more effective while assessing how well this approach works.
This trial tests a shorter course of radiation combined with chemotherapy and immunotherapy to treat mid- to low rectal cancer. The goal is to potentially improve outcomes while reducing side effects.
This trial tests a short course of radiation therapy combined with chemotherapy for people with stage II or III rectal cancer. It’s designed to see whether this approach is safe and effective before or around cancer surgery.
This trial tests a shorter radiation course combined with two chemotherapy drugs and an immunotherapy drug for people with locally advanced rectal cancer that is microsatellite stable. The goal is to shrink the tumor before surgery, which may improve outcomes with fewer side effects.
This trial compares a new treatment approach—short-course radiation followed by an immunotherapy drug (PD-1 inhibitor) and chemotherapy (FOLFOX)—to the standard long-course chemoradiation for people with a specific type of advanced rectal cancer that is pMMR/MSS. The goal is to see if the shorter treatment works as well or better.
Hear when a new Adenocarcinoma of the Rectum trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.